Reduced TRPC6 mRNA levels in the blood cells of patients with Alzheimer's disease and mild cognitive impairment
R Lu, J Wang, R Tao, J Wang, T Zhu, W Guo, Y Sun, H Li, Y Gao, W Zhang, CJ Fowler, Q Li, S Chen, Z Wu, CL Masters, C Zhong, N Jing, Y Wang, Y Wang
MOLECULAR PSYCHIATRY | NATURE PUBLISHING GROUP | Published : 2018
Transient receptor potential canonical 6 (TRPC6) inhibits β-amyloid (Aβ) production. Hyperforin, the TRPC6 agonist, reduces Aβ levels and improves cognitive performance in Alzheimer's disease (AD) models. However, it's unknown whether TRPC6 expression is changed in AD patients. In this case-control study, we measured TRPC6 expression levels in the peripheral blood cells of four independent AD sets from five hospitals and one mild cognitive impairment (MCI) set from a local community (229 AD, 70 MCI, 40 Parkinson disease and 359 controls from China, total n=698) using quantitative real-time PCR assay. We found a specific reduction of TRPC6 mRNA levels in four AD sets and one MCI set. The medi..View full abstract
Awarded by National Key Research and Development Program Foundation of China
This work was partially supported by the grants from the National Key Research and Development Program Foundation of China (2016YFC1306400), and from the Origincell Technology Group Co. Ltd, China. The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript. RL and JFW did the experiments and wrote the manuscript. YMS, HLL, YG, WZ, YJW, SDC, CJZ and ZYW made diagnosis of patients and collected clinical samples. JW, CJF, QXL and CLM did the experiments with the AIBL samples. RT and NHJ did establishment and induction of iPSCs. TZ repeated some experiments. RL and JFW analyzed the data. YZW supervised the project and wrote the manuscript. RL and YZW have full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.